Junye Wang

Prof. Junye Wang


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
WZWenyu Zhai
Wenyu Zhai
CZChao Zhang
Chao Zhang
FDFangfang Duan
Fangfang Duan
JXJingdun Xie
Jingdun Xie
SDShuqin Dai
Shuqin Dai
JWJunye Wang
Junye Wang
Background: Static tumor features before initiating anti-tumor treatment were insufficient to distinguish responding from non-responding tumors under the selective pressure of immuno-therapy. Herein we investigated the longitudinal dynamics of peripheral blood inflammatory indexes (dPBI) and its value in predicting major pathological response (MPR) in non-small cell lung cancer (NSCLC).Methods: A total of 147 patients with NSCLC who underwent neoadjuvant immunochemotherapy were retrospectively reviewed as training cohort, and 26 NSCLC patients from a phase II trial were included as validation cohort. Peripheral blood inflammatory indexes were collected at baseline and as posttreatment status; their dynamics were calculated as their posttreatment values minus their baseline level. Least absolute shrinkage and selection operator algorithm was utilized to screen out predictors for MPR, and a MPR score was integrated. We constructed a model incorporating this MPR score and clinical predictors for predicting MPR and evaluated its predictive capacity via the area under the curve (AUC) of the receiver operating characteristic and calibration curves. Furthermore, we sought to interpret this MPR score in the context of micro-RNA transcriptomic analysis in plasma exosomes for 12 paired samples (baseline and posttreatment) obtained from the training cohort.Results: Longitudinal dynamics of monocyte–lymphocyte ratio, platelet-to-lymphocyte ratio, platelet-to-albumin ratio, and prognostic nutritional index were screened out as significant indicators for MPR and a MPR score was integrated, which was further identified as an independent predictor of MPR. Then, we constructed a predictive model incorporating MPR score, histology, and differentiated degree, which discriminated MPR and non-MPR patients well in both the training and validation cohorts with an AUC value of 0.803 and 0.817, respectively. Furthermore, micro-RNA transcriptomic analysis revealed the association between our MPR score and immune regulation pathways. A significantly better event-free survival was seen in subpopulations with a high MPR score.Conclusion: Our findings suggested that dPBI reflected responses to neoadjuvant immuno-chemotherapy for NSCLC. The MPR score, a non-invasive biomarker integrating their dynamics, captured the miRNA transcriptomic pattern in the tumor microenvironment and distinguished MPR from non-MPR for neoadjuvant immunochemotherapy, which could support the clinical decisions on the utilization of immune checkpoint inhibitor-based treatments in NSCLC patients.

8 December 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
WZWenyu Zhai
Wenyu Zhai
DLDachuan Liang
Dachuan Liang
FDFangfang Duan
Fangfang Duan
WWWingshing Wong
Wingshing Wong
QYQihang Yan
Qihang Yan
JWJunye Wang
Junye Wang
The value of lung adenocarcinoma (LUAD) subtypes and ground glass opacity (GGO) in pathological stage IA invasive adenocarcinoma (IAC) has been poorly understood, and reports of their association with each other have been limited. In the current study, we retrospectively reviewed 484 patients with pathological stage IA invasive adenocarcinoma (IAC) at Sun Yat-sen University Cancer Center from March 2011 to August 2018. Patients with at least 5% solid or micropapillary presence were categorized as high-risk subtypes. Independent indicators for disease-free survival (DFS) and overall survival (OS) were identified by multivariate Cox regression analysis. Based on these indicators, we developed prognostic nomograms of OS and DFS. The predictive performance of the two nomograms were assessed by calibration plots. A total of 412 patients were recognized as having the low-risk subtype, and 359 patients had a GGO. Patients with the low-risk subtype had a high rate of GGO nodules (p < 0.001). Multivariate Cox regression analysis showed that the high-risk subtype and GGO components were independent prognostic factors for OS (LUAD subtype: p = 0.002; HR 3.624; 95% CI 1.263–10.397; GGO component: p = 0.001; HR 3.186; 95% CI 1.155–8.792) and DFS (LUAD subtype: p = 0.001; HR 2.284; 95% CI 1.448–5.509; GGO component: p = 0.003; HR 1.877; 95% CI 1.013–3.476). The C-indices of the nomogram based on the LUAD subtype and GGO components to predict OS and DFS were 0.866 (95% CI 0.841–0.891) and 0.667 (95% CI 0.586–0.748), respectively. Therefore, the high-risk subtype and GGO components were potential prognostic biomarkers for patients with stage IA IAC, and prognostic models based on these indicators showed good predictive performance and satisfactory agreement between observational and predicted survival.

3 September 2022 in Cancer Medicine
Verified
Journal Article
Open access
WZWenyu Zhai
Wenyu Zhai
YLYongzhe Li
Yongzhe Li
FDFangfang Duan
Fangfang Duan
JWJunye Wang
Junye Wang
ZZZe-Rui Zhao
Ze-Rui Zhao
HLHao Long
Hao Long
Background: Inflammation is known to have an intricate relationship with tumorigenesis and tumor progression while it is also closely related to tumor immune microenvironment. Whereas the role of inflammation‐related genes (IRGs) in lung squamous carcinoma (LUSC) is barely understood. Herein, we recognized IRGs associated with overall survival (OS), built an IRGs signature for risk stratification and explored the impact of IRGs on immune infiltration landscape of LUSC patients.Methods: The RNA‐sequencing and clinicopathological data of LUSC patients were downloaded from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) database, which were defined as training and validation cohorts. Cox regression and least absolute shrinkage and selection operator analyses were performed to build an IRG signature. CIBERSORT, microenvironment cell populations‐counter and tumor immune dysfunction and rejection (TIDE) algorithm were used to perform immune infiltration analysis.Results: A two‐IRG signature consisting of KLF6 and SGMS2 was identified according to the training set, which could categorize patients into two different risk groups with distinct OS. Patients in the low‐risk group had more anti‐tumor immune cells infiltrated while patient with high‐risk had lower TIDE score and higher levels of immune checkpoint molecules expressed. The IRG signature was further identified as an independent prognostic factor of OS. Subsequently, a prognostic nomogram including IRG signature, age, and cancer stage was constructed for predicting individualized OS, whose concordance index values were 0.610 (95% CI: 0.568–0.651) in the training set and 0.652 (95% CI: 0.580–0.724) in validation set. Time‐dependent receiver operator characteristic curves revealed that the nomogram had higher prediction accuracy compared with the traditional tumor stage alone.Conclusion: The IRG signature was a predictor for patients with LUSC and might serve as a potential indicator of the efficacy of immunotherapy. The nomogram based on the IRG signature showed a relatively good predictive performance in survival.

3 September 2020 in Research Square
Verified
Preprint
Open access
PDF file
WZWenyu Zhai
Wenyu Zhai
FDFangfang Duan
Fangfang Duan
YZYuzhen Zheng
Yuzhen Zheng
QYQihang Yan
Qihang Yan
SDShuqin Dai
Shuqin Dai
JWJunye Wang
Junye Wang
Background: The examination of lymph nodes (LNs) plays an important role in the nodal staging of non-small cell lung cancer (NSCLC). For patients without LN metastasis, the main role of thorough LN examination is accurate staging, which weakens the effect of staging migration. To date, on the role of hilar and intrapulmonary (N1) station LNs has not been fully appreciated. In this study, we aimed to confirm the significance of N1 LNs in long-term survival for stage IA-IIA NSCLC patients and to find the minimum number of LN to examine.Methods: The data of patients who underwent radical lobectomy and were confirmed as having nonmetastatic LNs from January 2008 to March 2018 were retrospectively screened. Pathology records were reviewed for the number of LNs examined. The Kaplan-Meier method and Cox regression model were used to identify survival and prognostic factors.Results: The median number of resected N1 LNs was 8. The number of patients with 0-2 N1 LNs, 3-5 N1 LNs, 6-8 N1 LNs, 9-11 N1 LNs and more than 11 N1 LNs examined was 181, 425, 477, 414 and 531, respectively. Sex (P=0.004), age (P<0.001), tumor size (P=0.004), differentiation degree (P=0.001) and number of N1 LNs examined (P=0.008) were independent prognostic factors of overall survival. Gender (P=0.006), age (P=0.031), tumor size (P=0.001), differentiation degree (P=0.001), vascular invasion (P=0.034) and number of N1 LNs examined (P=0.007) were independent prognostic factors of disease-free survival. Compared with patients with 0-5 N1 LNs examined, patients with more than 5 N1 LNs examined had better OS (P=0.015) and had better DFS (P=0.015) if only a landmark 5-year follow-up was performed.Conclusion: Increasing the number of N1 LNs examination might improve the long-term survival of T1-2N0 NSCLC patients. These data indicate that the at least 6 N1 nodes examined is an essential part in surgical and pathological management but cannot prove this. This finding should be confirmed in a large, prospective randomized clinical study.

1 January 1991
Verified
Book Chapter
Closed access
XXXiang Xun-Xian
Xiang Xun-Xian
HYHu Ying
Hu Ying
XLXu Li-Qun
Xu Li-Qun
JWJunye Wang
Junye Wang
LDLi Ding-Jiou
Li Ding-Jiou
SZSun Zhen-Qun
Sun Zhen-Qun

5 May 2021 in Research Square
Verified
Preprint
Open access
PDF file
WZWenyu Zhai
Wenyu Zhai
FDFangfang Duan
Fangfang Duan
LDLi Dongxia
Li Dongxia
QYQihang Yan
Qihang Yan
SDShuqin Dai
Shuqin Dai
JWJunye Wang
Junye Wang
Background Despite the heterogeneity among patients with stage IB-IIA non-small cell lung cancer (NSCLC), clinical applicable model to identify those patients to receive adjuvant chemotherapy after radical resection is limited. We aimed to developed a clinical tool of benefits from adjuvant chemotherapy for risk stratification and individualized management in this heterogeneous patient population. Methods Between January 2008 and March 2018, patients with T2N0M0 NSCLC at Sun Yat-sen University Cancer Center were retrospectively retrieved. Survival curves were estimated by means of the Kaplan-Meier method and compared with the long-rank test. We used the Cox hazard regression models to identify the prognostic factors associated with the disease-free survival (DFS) and overall survival (OS). To reduce the possible effects of bias, propensity score matching (PSM) was implemented in a 1:1 ratio to. Subgroup analysis was further performed based on the quantized clinical risk score (CRS) derived from the prognostic variates and epidermal growth factor receptor (EGFR) mutation status. Results A total of 1063 patients with T2N0M0 NSCLC were enrolled in this retrospective study, 272 patients among them received adjuvant chemotherapy. Before PSM, Patients with a high-CRS (>1) had a significant worse OS and DFS. After PSM, the baseline characteristics of 270 pairs of patients were matched well. A significant improvement in OS was associated with adjuvant chemotherapy for patients with a high-CRS, while adjuvant chemotherapy was a positive independent prognostic factor for OS and DFS in patients with wild-type EGFR. The interaction analysis showed an apparent interaction effect between adjuvant chemotherapy and EGFR-activating mutations as well as chemotherapy regimens and histology.Conclusions Clinical risk score can be used to predict the prognosis of patients with stage IB-IIA NSCLC. Adjuvant chemotherapy could improve the outcome of patients after surgery, especially for those with clinical risk score over 1. Patients with non-squamous cell histology receiving pemetrexed plus platinum might benefit more, but not in those with EGFR-activating mutations.